Silencing METTL3 expression in GBM can significantly inhibit tumour growth and prolong mouse survival time, which is consistent with clinical observations that an increase in METTL3 expression is consistent with the poor survival of patients with GBM. The gene discussed is METTL3; the disease is neoplasm.